BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced that at BIND’s annual meeting of stockholders held today the company’s stockholders elected Mr. Charles A. Rowland, Jr., CPA, most recently the Vice President and Chief Financial Officer of ViroPharma Incorporated, to its Board of Directors.
Help employers find you! Check out all the jobs and post your resume.
